Articles Tagged With: cabotegravir
-
WHO Updates Guidance on Long-Acting HIV Prophylaxis
International group suggests adding injectable cabotegravir to list of prevention tools.
-
First Injectable Pre-Exposure Prophylaxis Receives FDA Approval
Researchers hope this long-acting solution every will boost PrEP adherence rates among those at risk for contracting HIV.
-
Cabotegravir Extended-Release and Rilpivirine Injectable Suspension (Cabenuva) and Cabotegravir Tablets (Vocabria)
Cabotegravir/rilpivirine (CAB/RPV) should be prescribed to treat HIV-1-infected adults. This combination should replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen with no history of treatment failure and no known or suspected resistance to ether CAB or RPV.
-
Dual Combination ART with Cabotegravir and Rilpivirine Is Effective for Maintaining HIV Virological Suppression
Results of the phase 2 LATTE study show that after 24 weeks of induction triple therapy, maintenance therapy with cabotegravir (a long-acting dolutegravir analogue) and rilpivirine led to virological suppression in 82% of patients, compared to 71% who received efavirenz plus two NRTIs.